ImmunoGen Inc.

05/23/2022 | Press release | Distributed by Public on 05/23/2022 04:39

ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravtansine in Ovarian Cancer by US Food and Drug Administration with Priority Review